Back to Stocks

ASTH

Astrana Health, Inc.
7 filings tracked
healthcarehealthcare managementMID ($2B-10B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Astrana Health has reached a pivotal scale inflection point, reporting a 56% surge in quarterly revenue to $965.1 million.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the headline growth, Astrana's expansion is heavily leveraged, with long-term debt now totaling $980 million following the Prospect acquisition.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every ASTH filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company in the midst of a high-stakes transformation. Astrana has successfully scaled its footprint and revenue through aggressive M&A, but this growth has come at the cost of a significantly heavier debt load and increased operational complexity. The divergence between the explosive Adjusted EBITDA growth and the rising medical liabilities creates a tension between short-term reporting wins and long-term solvency risks. Ultimately, the investment thesis now hinges on the company's ability to execute the Prospect integration and maintain its leverage ratios. While the Care Enablement segment provides a promising path toward high-margin software-like scalability, the underlying risk remains tied to the volatility of medical costs and the concentration of payer contracts. Investors must weigh the ability to capture value-based care efficiencies against the risks of a highly leveraged balance sheet and unstable internal financial controls.

Selected Quarter

Core Takeaway

Astrana has successfully scaled to a billion-dollar revenue run rate via the Prospect acquisition, but the move has significantly increased leverage and operational risk.

Investor Lens

The trade-off between aggressive top-line growth and the ability to manage a ballooning debt and medical liability profile.

Watch Next

Remediation of material weakness in internal controls and 2027 Medicare Advantage rate impact.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.23Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 8

Revenue grew 56% to $965.1 million, driven by the Prospect acquisition.

earnings beat
80%
bullishMay 8

Care Enablement segment revenue surged 122% with a 23% operating margin.

margin expansion
70%
bearishMay 8

Total debt increased to $1.04 billion to fund acquisitions, increasing interest expense.

debt restructure
60%
neutralMay 8

Management identified a material weakness in internal control over financial reporting.

regulatory action
40%
bullishMay 8

Revenue grew 56% to $965.1 million, driven by the Prospect acquisition.

earnings beat
80%
bullishMay 8

Care Enablement segment revenue surged 122% with a 23% operating margin.

margin expansion
70%
bearishMay 8

Total debt increased to $1.04 billion to fund acquisitions, increasing interest expense.

debt restructure
60%
neutralMay 8

Management identified a material weakness in internal control over financial reporting.

regulatory action
40%
bullishMay 8

Revenue grew 56% to $965.1 million, driven by the Prospect acquisition.

earnings beat
80%
bullishMay 8

Care Enablement segment revenue surged 122% with a 23% operating margin.

margin expansion
70%
bearishMay 8

Total debt increased to $1.04 billion to fund acquisitions, increasing interest expense.

debt restructure
60%
neutralMay 8

Management identified a material weakness in internal control over financial reporting.

regulatory action
40%
bullishMay 8

Revenue grew 56% to $965.1 million, driven by the Prospect acquisition.

earnings beat
80%
bullishMay 8

Care Enablement segment revenue surged 122% with a 23% operating margin.

margin expansion
70%
bearishMay 8

Total debt increased to $1.04 billion to fund acquisitions, increasing interest expense.

debt restructure
60%
neutralMay 8

Management identified a material weakness in internal control over financial reporting.

regulatory action
40%
bullishMay 8

Revenue grew 56% to $965.1 million, driven by the Prospect acquisition.

earnings beat
80%
bullishMay 8

Care Enablement segment revenue surged 122% with a 23% operating margin.

margin expansion
70%
bearishMay 8

Total debt increased to $1.04 billion to fund acquisitions, increasing interest expense.

debt restructure
60%
neutralMay 8

Management identified a material weakness in internal control over financial reporting.

regulatory action
40%
bullishMay 8

Revenue grew 56% to $965.1 million, driven by the Prospect acquisition.

earnings beat
80%
bullishMay 8

Care Enablement segment revenue surged 122% with a 23% operating margin.

margin expansion
70%
bearishMay 8

Total debt increased to $1.04 billion to fund acquisitions, increasing interest expense.

debt restructure
60%
neutralMay 8

Management identified a material weakness in internal control over financial reporting.

regulatory action
40%
bullishMay 8

Revenue grew 56% to $965.1 million, driven by the Prospect acquisition.

earnings beat
80%
bullishMay 8

Care Enablement segment revenue surged 122% with a 23% operating margin.

margin expansion
70%
bearishMay 8

Total debt increased to $1.04 billion to fund acquisitions, increasing interest expense.

debt restructure
60%
neutralMay 8

Management identified a material weakness in internal control over financial reporting.

regulatory action
40%

Filing History

10-QMay 8, 2026
Expand Sequence

The Q1 2026 filing reveals a company in the midst of a high-stakes transformation. Astrana has successfully scaled its footprint and revenue through aggressive M&A, but this growth has come at the cost of a significantly heavier debt load and increased operational complexity. The divergence between the explosive Adjusted EBITDA growth and the rising medical liabilities creates a tension between short-term reporting wins and long-term solvency risks. Ultimately, the investment thesis now hinges on the company's ability to execute the Prospect integration and maintain its leverage ratios. While the Care Enablement segment provides a promising path toward high-margin software-like scalability, the underlying risk remains tied to the volatility of medical costs and the concentration of payer contracts. Investors must weigh the ability to capture value-based care efficiencies against the risks of a highly leveraged balance sheet and unstable internal financial controls.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.